Mack Eye Center Report issue

Academic/Hospital Phase 1

Organization Overview

First Clinical Trial
2013
NCT02009709
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Alternative names

Robert Mack, M.D.

Active Ingredients

Drugs in Phase 1 Trials (1)

riboflavin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dilatation, Pathologic (Phase 1)

Keratoconus (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1